Date published: 2026-7-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

TFIIH p80 Antibody (184.7): sc-101174

4.0(4)
Write a reviewAsk a question

Datasheets
  • TFIIH p80 Antibody (184.7) is a mouse monoclonal IgG1 κ, cited in 8 publications, provided at 100 µg/ml
  • raised against recombinant TFIIH p80 of human origin
  • recommended for detection of TFIIH p80 of mouse, rat and human origin by WB, IP and ELISA
  • At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TFIIH p80 Antibody (184.7). This work is in progress.
Gene Editing Promo Banner

QUICK LINKS

SEE ALSO...

TFIIH p80 Antibody (184.7) is a mouse monoclonal IgG1 antibody that detects TFIIH p80 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). TFIIH p80, also known as XPD or ERCC2, plays a crucial role in transcription and DNA repair mechanisms, making TFIIH p80 essential for maintaining genomic stability. TFIIH p80 functions as part of the TFIIH complex, located in the nucleus and involved in unwinding DNA during transcription and nucleotide excision repair. TFIIH p80 is vital for recruiting other repair factors, and TFIIH p80 dysfunction can lead to various genetic disorders, including xeroderma pigmentosum, characterized by extreme sensitivity to UV light and predisposition to skin cancer. The TFIIH complex′s ability to coordinate transcription and repair underscores TFIIH p80′s importance in cellular health and mutation prevention, highlighting TFIIH p80′s significance in both basic research and clinical applications. Anti-TFIIH p80 antibody (184.7) serves as an invaluable tool for researchers studying gene expression and DNA repair pathways.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA

LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences

TFIIH p80 Antibody (184.7) References:

  1. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.  |  Xue, H., et al. 2012. PLoS One. 7: e43431. PMID: 23028453
  2. Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis.  |  Qiu, M., et al. 2013. PLoS One. 8: e72251. PMID: 23977265
  3. XPD suppresses cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC.  |  Xiao, Z., et al. 2019. Cell Biosci. 9: 6. PMID: 30627419
  4. XPD/ERCC2 mutations interfere in cellular responses to oxidative stress.  |  Lerner, LK., et al. 2019. Mutagenesis. 34: 341-354. PMID: 31348825
  5. Cloning of the XPD gene and its function in malignant melanoma cells.  |  Wang, Y., et al. 2020. Oncol Lett. 20: 1803-1809. PMID: 32724423
  6. XPD Polymorphisms and Risk of Hepatocellular Carcinoma and Gastric Cancer: A Meta-Analysis.  |  Zhou, Q., et al. 2021. Technol Cancer Res Treat. 20: 1533033821990046. PMID: 33517857
  7. Phosphorylation of XPD drives its mitotic role independently of its DNA repair and transcription functions.  |  Compe, E., et al. 2022. Sci Adv. 8: eabp9457. PMID: 35977011
  8. NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression.  |  Sun, GF. and Ding, H. 2023. Neoplasma. 70: 340-349. PMID: 37498063
  9. Differing structures and dynamics of two photolesions portray verification differences by the human XPD helicase.  |  Fu, I., et al. 2023. Nucleic Acids Res. 51: 12261-12274. PMID: 37933861
  10. XPD stalled on cross-linked DNA provides insight into damage verification.  |  Kuper, J., et al. 2024. Nat Struct Mol Biol. 31: 1580-1588. PMID: 38806694

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

TFIIH p80 Antibody (184.7)

sc-101174
100 µg/ml
$339.00